marketing-medtech

**Founder:** Jean-Philippe Estrade (founding physician); Inès Ben Amor (CEO / decision-maker) — Dr Jean-Philippe Estrade — Président de SAS / founding gynecological surgeon; Inès Ben Amor — CEO (operating decision-maker) since 2022
**Background:** clinician | verified: True — Dr Jean-Philippe Estrade is a real gynecological surgeon (clinician): expert in gynecological and pelvi-perineal surgery, endometriosis surgery and robotic surgery; former surgeon at Marseille public hospitals (AP-HM), member of the Académie Nationale de Chirurgie, and President of the Société de Chirurgie Gynécologique et Pelvienne (since 2021). He co-founded the Luna / Luna for Health endometriosis app in 2017 and serves as co-founder and Chief Medical Officer (CMO) — not "Président de SAS." Inès Ben Amor is confirmed as CEO of Luna for Health, leading the company since 2022. She is an engineer (École des Mines de Saint-Étienne) with an EM Lyon Business School background, and is the operating decision-maker. So: Estrade = founding gynecological surgeon/clinician (CMO); Ben Amor = CEO/decision-maker since 2022. The "clinician" claim for Estrade is fully supported. Two minor corrections: Estrade's startup title is CMO/co-founder rather than "Président de SAS," and the legal name is the SAS behind the "Luna" / "Luna for Health" brand (the verbose 'Healthcare Digital Solution Intelligence & Application' label was not independently confirmed as the official entity name).
**Stage / fundraise:** Established growth-stage SaMD/femtech, NOT early. Legal unit (SIREN 839757333) created 2018-04-13 (the 2024-08-02 date in the brief is only the new Aix siege establishment). ~6-person team, CE-marked medical device already on market, 50k-80k users. Categorie INSEE: PME. / Grant/dilutive-light to date: ~€500k love money early on; Bpifrance i-Nov (France 2030) laureate for €756,000; selected to PariSanté Campus x Bpifrance digital-prevention accelerator (linked €100M fund). No confirmed priced VC round (Series A) announced as of June 2026 — public sources show grants + accelerator, not an equity raise.
**Regulatory trigger:** Already a CE-marked medical device (SaMD) — "1ère aide au diagnostic de l'endométriose" (LunaEndoScore), backed by a clinical study (~2,500 patients). So the CE/MDR first-marking milestone is largely behind them; ongoing trigger is MDR class evolution, AI-feature additions (AI Act / MDR change control) and reimbursement (PECAN / forfait) rather than an initial certification.
**Email:** contact@lunaforhealth.com (unconfirmed corporate pattern) (confidence low) — No personal address is published anywhere I found. Corporate domain is lunaforhealth.com (also luna-endometriose.com); a Tracxn profile references a redacted *@luna-endo.fr address. contact@lunaforhealth.com is an inferred generic mailbox, not a confirmed published address. Best route is the contact form at https://www.luna-endometriose.com/en/contact/ or LinkedIn DM to Inès Ben Amor.
**LinkedIn:** Inès Ben Amor (CEO): https://www.linkedin.com/posts/ines-ben-amor_startup-ines-ben-amor-ceo-de-luna-activity-7055228693605969920-Co-n ; Dr J-P Estrade: https://www.linkedin.com/in/jean-philippe-estrade-b3797971/ ; Company: https://fr.linkedin.com/company/lunaforhealth **Website:** https://www.lunaforhealth.com (also https://www.luna-endometriose.com)
**Score:** 4 -> Tier C
**Hook:** Caution: this lead does not match the early/non-technical/no-CTO ICP. Luna is founded 2018, already CE-marked, and has an in-house AI R&D team led by a data-science CEO. If still approached, the only honest angle is overflow capacity + MDR/AI-Act compliance evidence (SOUP register + requirements-to-code-to-test traceability) as they add AI features under change control and pursue reimbursement — i.e. OmDev as a flex senior team + compliance engine when their 5-person team is stretched across app + telemedicine + centres. Not a fit for the "no tech team / cheaper than hiring a CTO" pitch.

---

## Founder & background
Listed Président is **Dr Jean-Philippe Estrade** (b. 1971), a gynecological surgeon and international endometriosis expert (HPP Aix, CHPG Monaco, robotic surgery) who originated and directs Luna ([estrade](https://jeanphilippe-estrade.com/luna/)). The operating CEO since 2022 is **Inès Ben Amor** — École des Mines Saint-Étienne + EM Lyon, IT & Data Science PM background, VP French Tech Aix-Marseille ([lestalentes](https://www.lestalentes.fr/laureates/ines-ben-amor/)).
Profile = **clinician founder + tech/data CEO** — not finance/insurance, and the tech capability is already internal.
**Why OmDev fits:** Limited — the founder/CEO combo already covers product + AI, so the "non-technical, no-CTO" thesis does not hold.

## Funding & momentum
~€500k love money early; **Bpifrance i-Nov (France 2030) laureate, €756,000**; selected to the **PariSanté Campus x Bpifrance** digital-prevention accelerator (linked €100M fund) ([bpifrance](https://bigmedia.bpifrance.fr/nos-actualites/luna-une-solution-de-diagnostic-et-prise-en-charge-de-lendometriose)).
No confirmed priced VC round as of June 2026 — grant- and accelerator-funded, not in a visible equity raise.
**Why OmDev fits:** No urgent raise-driven build-out signal; grant runway favours their in-house team, not outsourcing.

## Product & regulatory
**Luna for Health** (iOS/Android, pkg `com.hdsi.luna`): endometriosis symptom tracking + **CE-marked diagnostic-aid questionnaire (LunaEndoScore)** validated on ~2,500 patients, plus telemedicine and physical Luna centres (HPP Aix, Marseille); ~80,000 users ([eurobiomed](https://eurobiomed.org/actualites/article-adherent/portrait-dentreprise-luna)).
The initial **CE/MDR marking is already done** — remaining triggers are MDR/AI-Act change control as AI features grow and reimbursement (PECAN).
**Why OmDev fits:** The compliance engine (SOUP register + requirements-to-code-to-test traceability) is relevant only for *ongoing* AI change-control, not a first certification.

## Pain & buying signals
Team is small (~6, with ~5 in AI R&D / Product / Marketing under a data-science CEO) — capable but stretched across app + telemedicine + multi-centre ops.
**No visible no-CTO or thin-dev-team gap**, which is the core OmDev hook; this is a growth-stage company that builds in-house.
**Why OmDev fits:** Best (weak) angle is **overflow senior capacity + MDR/AI-Act compliance evidence** when their team is stretched — not the cost-vs-hiring-a-team pitch. **Tier C — deprioritize; does not match the early / non-technical ICP.** Best contact: form at [luna-endometriose.com/en/contact](https://www.luna-endometriose.com/en/contact/) or LinkedIn DM to Inès Ben Amor.

---
**Sources:** https://recherche-entreprises.api.gouv.fr/search?q=839757333 · https://annuaire-entreprises.data.gouv.fr/etablissement/83975733300035 · https://www.lunaforhealth.com/ · https://jeanphilippe-estrade.com/luna/ · https://eurobiomed.org/actualites/article-adherent/portrait-dentreprise-luna · https://www.lestalentes.fr/laureates/ines-ben-amor/ · https://bigmedia.bpifrance.fr/nos-actualites/luna-une-solution-de-diagnostic-et-prise-en-charge-de-lendometriose · https://www.linkedin.com/in/jean-philippe-estrade-b3797971/ · https://fr.linkedin.com/company/lunaforhealth · https://play.google.com/store/apps/details?id=com.hdsi.luna · https://apps.apple.com/fr/app/luna-for-health-endom%C3%A9triose/id1585942826 · https://www.luna-endometriose.com/en/contact/